SA118400097B1 - تخليق جسيمات حمض الإيفلايونيك متناهي الصغر - Google Patents
تخليق جسيمات حمض الإيفلايونيك متناهي الصغرInfo
- Publication number
- SA118400097B1 SA118400097B1 SA118400097A SA118400097A SA118400097B1 SA 118400097 B1 SA118400097 B1 SA 118400097B1 SA 118400097 A SA118400097 A SA 118400097A SA 118400097 A SA118400097 A SA 118400097A SA 118400097 B1 SA118400097 B1 SA 118400097B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- ifflaionic
- solution
- synthesis
- acid nanoparticles
- acid
- Prior art date
Links
- DQOFFNPCGATPDE-MXMXHWDASA-N (1r,2r,4ar,6ar,6as,6br,8ar,12ar,14br)-1,4a,6a,6b,9,9,12a-heptamethyl-10-oxo-1,2,3,4,5,6,6a,7,8,8a,11,12,13,14b-tetradecahydropicene-2-carboxylic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(O)=O)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C DQOFFNPCGATPDE-MXMXHWDASA-N 0.000 title abstract 4
- DQOFFNPCGATPDE-UHFFFAOYSA-N Ifflaionic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(O)=O)C(C)C5C4=CCC3C21C DQOFFNPCGATPDE-UHFFFAOYSA-N 0.000 title abstract 4
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 239000000243 solution Substances 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
يشتمل تخليق Synthesis جسيمات حمض الإيفلايونيك المتناهية الصغر ifflaionic acid nanoparticles على إذابة مسحوق من حمض الإيفلايونيك ifflaionic acid في محلول كحولي an alcohol solution لتكوين محلول أول a first solution، بإضافة المحلول الأول إلى محلول مائي an aqueous solution تحت ظروف الموجات فوق الصوتية ultrasonic conditions لإنتاج محلول مذاب بتأثير الموجات الفوق صوتيه a sonicated solution، تقليب stirring المحلول المذاب بتأثير الموجات الفوق صوتيه the sonicated solution لمدة زمنية لإنتاج خليط a mixture، وتجفيد (التجفيف بالتجميد) freeze-drying الخليط the mixture لتوفير جسيمات حمض الإيفلايونيك المتناهية الصغر the ifflaionic acid nanoparticles.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/785,277 US9974750B1 (en) | 2017-10-16 | 2017-10-16 | Synthesis of ifflaionic acid nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA118400097B1 true SA118400097B1 (ar) | 2021-06-02 |
Family
ID=62122092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA118400097A SA118400097B1 (ar) | 2017-10-16 | 2018-10-10 | تخليق جسيمات حمض الإيفلايونيك متناهي الصغر |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US9974750B1 (ar) |
| SA (1) | SA118400097B1 (ar) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10086027B1 (en) * | 2018-03-01 | 2018-10-02 | King Saud University | Green synthesis of katononic acid nanosheets |
| US10856559B1 (en) * | 2019-09-09 | 2020-12-08 | King Saud University | Method of producing eggshell-derived nanoparticles |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045159B1 (en) | 2000-09-19 | 2006-05-16 | Rutgers, The State University Of New Jersey | Antiviral substances from plant cuticular and epiciticular material |
| US8168835B2 (en) | 2010-05-26 | 2012-05-01 | National Tsing Hua University | Method for preparing propargylic alcohol catalyzed by 2-morpholinoisobornane-10-thiol |
| WO2013006795A2 (en) | 2011-07-07 | 2013-01-10 | Humanitas International Foundation | Antiviral compositions and methods of their use |
| US20130012470A1 (en) | 2011-07-07 | 2013-01-10 | Humanitas Technology, LLC | Antiviral compositions and methods of their use |
-
2017
- 2017-10-16 US US15/785,277 patent/US9974750B1/en not_active Expired - Fee Related
-
2018
- 2018-10-10 SA SA118400097A patent/SA118400097B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9974750B1 (en) | 2018-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
| MX2017002085A (es) | Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido. | |
| PH12016500720A1 (en) | Stable formulation of insulin glulisine | |
| NZ719169A (en) | Heteroaryl butanoic acid derivatives as lta4h inhibitors | |
| MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
| CR20150444A (es) | Composición fertilizante y método para suspender fertilizante en una solución acuosa | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| PH12015500138A1 (en) | Composition for agent for external use | |
| SA118400097B1 (ar) | تخليق جسيمات حمض الإيفلايونيك متناهي الصغر | |
| MX2019008865A (es) | Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas. | |
| MX2016015261A (es) | Dispersion solida de allisartan isoproxilo y su composicion. | |
| PH12017500516A1 (en) | Compositions | |
| MX2016004328A (es) | Inmunopotenciador. | |
| NZ717101A (en) | Partial melt co-crystallization compositions | |
| MX2015016603A (es) | Composiciones de corticosteroides. | |
| MX2015016490A (es) | Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos. | |
| MX2023000348A (es) | Composicion que contiene ciclodextrina y busulfan. | |
| MX354220B (es) | Metodo para producir una dispersion estable de nano-particulas, la dispersion producida y el uso de la misma. | |
| AR098023A1 (es) | Un proceso para preparar isoxaflutol | |
| PH12017500863A1 (en) | Method of coalescing a susbtance | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| PH12016502059A1 (en) | Fast dissolving granulate | |
| MY182080A (en) | Method for manufacturing thickener composition | |
| MA39009A (fr) | Compositions pharmaceutiques comprenant un agent actif | |
| IN2013CH04314A (ar) |